Nanjing Leads Biolabs (SEHK:9887) reported that China's National Medical Products Administration accepted its NDA for ...
The study is led by Professor Shen Lin of Peking University Cancer Hospital. In the safety run‑in stage, Opamtistomig in combination with chemotherapy demonstrated encouraging efficacy signals in ...
A team of researchers at Roswell Park Comprehensive Cancer Center, led by Dhyan Chandra, Ph.D., has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare and hard-to-treat ...
UCLA researchers have uncovered a hidden weakness in some of the deadliest cancers, revealing a potential new strategy for targeting tumors that have long resisted treatment. Small cell neuroendocrine ...
Experts unpack neuroendocrine carcinoma vs tumors, key pathology markers, and high-risk features shaping prognosis and treatment decisions. Welcome back to another AJMC Peer Exchange series. In this ...
UCLA researchers have uncovered a hidden weakness in some of the deadliest cancers, revealing a potential new strategy for targeting tumors that have long resisted treatment. Small cell neuroendocrine ...
Experts outline evolving EP-NEC care: smarter combo therapies, DLL3 targets, precise pathology, and why early clinical trials matter. In the final episode, ‘The Road Ahead: Personalized Therapy, ...
Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study In this European multicenter cohort, clinical data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results